K. Röhss

发表

Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response

Justin C. Earp, C. Garnett, J. van der Walt, 2017, Journal of pediatric gastroenterology and nutrition.

Prevention of Relapse of Healed Reflux Esophagitis is Related to the Duration of Intragastric pH>4

D. Levine, M. Åstrand, D. Johnson, 2010, Journal of clinical gastroenterology.

A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

D. Levine, M. Åstrand, P. Katz, 2010, Alimentary pharmacology & therapeutics.

Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies

C. Wilder-Smith, K. Röhss, P. Bondarov, 2005, European journal of gastroenterology & hepatology.

A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

T. Andersson, K. Röhss, M. Niazi, 2004, European Journal of Clinical Pharmacology.

Pharmacokinetic study of esomeprazole in patients with hepatic impairment

E. Björnsson, H. Sjövall, K. Röhss, 2002, European journal of gastroenterology & hepatology.

Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole

T. Andersson, K. Röhss, G. Hasselgren, 2001, Clinical pharmacokinetics.

Pharmacokinetic Study of Esomeprazole in the Elderly

T. Andersson, K. Röhss, G. Hasselgren, 2001, Clinical pharmacokinetics.

Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole

T. Andersson, K. Röhss, E. Bredberg, 2001, Alimentary pharmacology & therapeutics.

Drug Interaction Studies with Esomeprazole, the (S)-Isomer of Omeprazole

T. Andersson, K. Röhss, G. Hasselgren, 2001, Clinical pharmacokinetics.

Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects

T. Andersson, K. Röhss, E. Bredberg, 2000, European Journal of Clinical Pharmacology.

Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects.

P. Lundborg, K. Röhss, L. Olbe, 1993, Scandinavian journal of gastroenterology.

Pharmacokinetics of Omeprazole Given by Continuous Intravenous Infusion to Patients with Varying Degrees of Hepatic Dysfunction

J. Piqué, K. Röhss, G. Hasselgren, 2002, Clinical pharmacokinetics.

Esomeprazole 20mg Provides More Effective Intragastric Acid Control than Maintenance-Dose Rabeprazole, Lansoprazole or Pantoprazole in Healthy Volunteers

C. Wilder-Smith, K. Röhss, E. Nauclér, 2004, Clinical drug investigation.

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

C. Wilder-Smith, K. Röhss, T. Lind, 2004, European Journal of Clinical Pharmacology.

Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules.

S. Meuwissen, K. Röhss, H. Festen, 1987, British journal of clinical pharmacology.

Bioavailability of Omeprazole as Enteric Coated (EC) Granules in Conjunction with Food on the First and Seventh Days of Treatment

T. Andersson, P. Lundborg, K. Röhss, 1990 .

Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study

K. Röhss, L. Svedberg, P. Bondarov, 2004, Alimentary pharmacology & therapeutics.

Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg

C. Wilder-Smith, K. Röhss, H. Rydholm, 2000 .

Optimization of acid suppression for patients with peptic ulcer bleeding: an intragastric pH‐metry study with omeprazole

K. Röhss, G. Hasselgren, P. Sinclair, 1998, European journal of gastroenterology & hepatology.

Esomeprazole, the S-isomer of omeprazole, is optically stable in humans

P. Lagerström, K. Röhss, M. Niazi, 2000 .

Pharmacokinetics of esomeprazole in patients with liver cirrhosis

K. Röhss, M. Hassan-Alin, J. Holmberg, 2000 .

Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg

K. Röhss, L. Nyman, H. Rydholm, 2000, American Journal of Gastroenterology.

Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.

P. Lundborg, J. Jansen, L. Baak, 1988, Gut.

The effects of dose and timing of esomeprazole administration on 24‐h, daytime and night‐time acid inhibition in healthy volunteers

K. Röhss, P. Nagy, M. Sagar, 2010, Alimentary pharmacology & therapeutics.

Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.

K. Röhss, T. Lind, J. Kilhamn, 2007, International journal of clinical pharmacology and therapeutics.

Effect of Esomeprazole 40 mg vs Omeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease

H. Hedenström, K. Röhss, G. Hasselgren, 2002, Digestive Diseases and Sciences.

Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.

K. Röhss, B. Olofsson, A. Thomson, 1997, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Esomeprazole 40 mg Provides Improved Intragastric Acid Control as Compared with Lansoprazole 30 mg and Rabeprazole 20 mg in Healthy Volunteers

C. Wilder-Smith, K. Röhss, O. Junghard, 2004, Digestion.

Acid control with esomeprazole and lansoprazole: A comparative dose–response study

C. Wilder-Smith, K. Röhss, T. Lind, 2007, Scandinavian journal of gastroenterology.

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.

T. Andersson, A. Walan, K. Röhss, 1998, British journal of clinical pharmacology.

Acid Control Cannot Be Improved with a Modified-Release Formulation of a Proton Pump Inhibitor Compared with Twice-Daily Dosing of the Conventional Formulation

C. Wilder-Smith, K. Röhss, P. Nagy, 2010, Digestive Diseases and Sciences.

Effect of Increasing Esomeprazole and Pantoprazole Doses on Acid Control in Patients with Symptoms of Gastro-Oesophageal Reflux Disease

C. Wilder-Smith, K. Röhss, T. Lind, 2008, Clinical drug investigation.

Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors

J. Dent, D. Johnson, P. Kahrilas, 2015, Therapeutic advances in gastroenterology.

Esomeprazole 40 Mg provides more effective acid control than standard doses of all other proton pump inhibitors

C. Wilder-Smith, K. Röhss, G. Hasselgren, 2001 .

Pharmacokinetics (PK) and dose-response relationship of esomeprazole (E)

T. Andersson, K. Röhss, E. Bredberg, 2000 .

Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects.

T. Andersson, K. Röhss, M. Niazi, 2006, International journal of clinical pharmacology and therapeutics.

Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.

K. Röhss, T. Lind, L. Olbe, 1992, Digestion.

Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease

K. Röhss, G. Hasselgren, Lind, 2000, Alimentary pharmacology & therapeutics.

Pharmacokinetics of esomeprazole following varying intravenous administration rates.

K. Röhss, P. Bondarov, M. Niazi, 2005, Basic & clinical pharmacology & toxicology.

Intravenous Esomeprazole 40mg is Effective for the Control of Intragastric Acid Levels Whether Given as a 3-Minute Injection or a 30-Minute Infusion

C. Wilder-Smith, K. Röhss, P. Bondarov, 2005, Clinical drug investigation.

Esomeprazole 40 mg administered intravenously (IV) as a 3-minute injection or 30-minute infusion provides the same effective acid control in healthy subjects

C. Wilder-Smith, K. Röhss, P. Bondarov, 2003 .